Green Thumb Is Paying $70 Million a Year to License Its Own Brands

Green Thumb Industries dropped Q1 2026 results after the bell yesterday, and by the standards of the U.S. cannabis sector, this is about as clean a quarter as you're going to see. Revenue of $300.2 million, up 7.4% year-over-year. Net income of $15.4 million. Cash flow from operations of $76 million. A $344.5 million cash pile sitting against $289.9 million in total debt — making Green Thumb one of exactly two major MSOs currently in a net cash position.

The stock opened today around $8.20 on the OTCQX, up modestly from yesterday's $8.10 close. Analysts had been expecting a slight loss after management guided for a mid-single-digit sequential revenue decline on the Q4 call. What they got instead was a $0.07 EPS beat powered by a couple of one-time items and a surprisingly strong operating quarter.

But the headline numbers, as always in cannabis, only tell you about half of what's actually happening. The more interesting story is structural: how Green Thumb is methodically rebuilding itself into something that looks less like a multi-state cannabis operator and more like a franchise holding company with a Nasdaq-listed brand licensor attached to it. That transformation is happening in real time, and Q1 is the first quarter where you can see all the moving parts at once.

By the Numbers

Q1 2026 vs. Q4 2025 (QoQ) — vs. Q1 2025 (YoY)

Revenue: $300.2M — down 3.5% QoQ, up 7.4% YoY

Gross Margin: 47.9% — up 250 bps QoQ, down 340 bps YoY

Normalized EBITDA: $93.5M (31.2%) — down from $100.2M (32.2%) QoQ, up from $85.2M (30.5%) YoY

Operating Income: $40.7M — up from $19.0M QoQ, down from $42.5M YoY

Net Income: $15.4M ($0.07/share) — down from $83.2M QoQ*, up from $8.3M YoY

Operating Cash Flow: $76.0M — down from $90.0M QoQ, up from $68.5M YoY

Cash Position: $344.5M — up from $274.3M QoQ (+$70.2M)

Net Cash: $54.6M — up from $29.4M QoQ (+$25.2M)

Same-Store Comps: -0.5% (base of 100 stores)

Effective Tax Rate: 76.2% — down from 78.9% YoY (still 280E territory)

Shares Repurchased (Q1): 6.05M shares at avg. $5.51 ($33.3M total)

*Q4 2025 net income inflated by $125.9M in warrant fair value adjustments.

Trailing Revenue Trend: $279.5M → $293.3M → $291.4M → $311.1M → $300.2M — YoY acceleration from +1.6% (Q3) to +5.7% (Q4) to +7.4% (Q1), driven by Minnesota adult-use durability plus Connecticut and Florida strength. The sequential dip was guided for — seasonality hits cannabis retail hard in Q1, and same-store comps of -0.5% on 100 stores was the best print in four quarters.

The margin story in two sentences: YoY gross margin compression (340 bps) is almost entirely the new RYTHM license fees ($9M hitting COGS vs. zero last year) plus price wars in Illinois, Pennsylvania, and New Jersey. Sequentially, margins are recovering — 45.4% in Q4 to 47.9% in Q1 — and Normalized EBITDA margin expanded YoY from 30.5% to 31.2%, meaning the core business is actually getting more efficient, not less.

The balance sheet in one sentence: $344.5M cash against $289.9M total debt puts Green Thumb in a net cash position of $54.6M — one of two MSOs that can say that — even after spending $33.3M on buybacks and absorbing a $50M credit facility expansion in the quarter.

The $70 Million Brand Tax

Here's the line item that nobody in cannabis media is scrutinizing hard enough.

Effective April 1, 2026, Green Thumb now pays $70 million per year in fixed licensing fees to RYTHM, Inc. (Nasdaq: RYM) for the right to use its own brand portfolio: RYTHM, Dogwalkers, incredibles, Beboe, Doctor Solomon's, &Shine, and Good Green. That's $17.5 million per quarter flowing from the operating company to the brand holding company, with annual escalators tied to 2x CPI — capped at 10% year-over-year.

In Q1, the fee was still on the old revenue-based structure, coming in at $9.0 million. Starting Q2, it jumps to $17.5 million per quarter. At $70 million annually, that's 5.8% of trailing twelve-month revenue being siphoned from the plant-touching entity to the federally compliant one.

Why does this matter? Because Ben Kovler — Green Thumb's founder, chairman, and CEO — is also the chairman and interim CEO of RYTHM, Inc. Green Thumb owns approximately 33% of RYTHM's common stock. These are related-party transactions structured specifically to give RYTHM predictable, cannabis-derived revenue in a form that Nasdaq is willing to tolerate for listing purposes. RYTHM itself just reported Q1 revenue of $13.3 million at a 78% gross margin, driven primarily by these licensing fees and its expanding hemp-derived THC beverage business (Señorita, now sold at the United Center in Chicago).

From an investor standpoint, the question is whether this is a feature or a bug. The bull case: Green Thumb shareholders indirectly own 33% of a Nasdaq-listed brand company whose equity is likely to re-rate dramatically if federal legalization ever opens up traditional capital markets. The bear case: you're paying $70 million a year in operating margin compression for the option value of an uplisting catalyst that may be years away, while the dual CEO structure creates governance questions that institutional investors will flag.

For Q1, the $9.0 million fee dropped gross margin from what would have been approximately 50.9% to the reported 47.9%. By Q2, when the full $17.5 million quarterly fee kicks in, the GAAP margin compression will look worse even if the underlying business is performing identically.

The Ascend Windfall and the RYTHM Dividend

Green Thumb's net income of $15.4 million looks impressive against Q1 2025's $8.3 million — an 85% increase. But let's be honest about what's driving it.

Total other income swung from negative $2.8 million a year ago to positive $22.4 million in Q1 2026. That $25.2 million swing came from two sources: a $17.0 million arbitration settlement won against Ascend Wellness Holdings (stemming from a 2018 agreement — the arbitrator originally awarded $19.7 million, Ascend settled for $17 million in February), and $6.5 million in equity method investment income from RYTHM, Inc.

Strip those out and total other income would have been negative $1.1 million — basically in line with a year ago. Operating income actually declined from $42.5 million in Q1 2025 to $40.7 million in Q1 2026, a 4.2% drop. The core business operations generated slightly less income, and two one-time or structural items papered it over.

That's not a criticism — the Ascend settlement is real cash, already collected, and the RYTHM equity income will likely recur. But investors need to understand that the operating trajectory and the earnings trajectory are telling different stories this quarter.

The 76.2% Problem

Green Thumb's effective tax rate in Q1 was 76.2%. On pre-tax income of $63.1 million, the company paid $48.1 million in taxes. Read that again: for every dollar of pre-tax profit, Green Thumb kept 24 cents.

This is the 280E anvil that every U.S. cannabis operator lives under, and it's worth contextualizing the magnitude. In Q1 2025, the effective rate was 78.9% ($31.3 million in tax on $39.7 million pre-tax). Year-over-year, the rate actually improved slightly — but it's still confiscatory by any normal corporate standard.

The rescheduling of medical cannabis to Schedule III, which became effective on April 22, 2026, changes the calculus going forward — but only for medical operations. Green Thumb's medical revenue mix varies significantly by state: some markets like Florida and Pennsylvania are still medical-only or medical-heavy, while adult-use states like Illinois and Connecticut generate the majority of revenue from recreational sales that remain subject to 280E.

Management flagged this in the press release: the 280E relief applies specifically to the medical portion of the business. Green Thumb hasn't broken out the precise medical-versus-adult-use revenue split, but based on their 14-state footprint and market mix, a reasonable estimate is 35-40% medical revenue. If 280E relief applies to that slice, the effective tax rate could drop into the 55-60% range starting Q2 — still painful, but a meaningful improvement that would flow directly to free cash flow.

The Buyback Machine

Since September 2023, Green Thumb has repurchased approximately 29 million shares for roughly $200 million, at an average cost around $6.90. With the stock trading at $8.20 today, every repurchased share is sitting on an unrealized gain of roughly 19% for remaining shareholders.

In Q1 alone, the company bought back 6.05 million shares at an average price of $5.51. Since quarter-end, they've accelerated — purchasing another 7.4 million shares, bringing year-to-date repurchases to 13.4 million shares for $77.7 million.

At Q1's weighted average share count of 230.6 million, those 29 million repurchased shares represent approximately 11.2% of what would have been the outstanding float — a massive capital return by any standard, and unheard of in cannabis where most operators are still diluting shareholders to stay alive.

The board also authorized an additional $100 million for repurchases in late April. Combined with the existing programs, Green Thumb now has significant remaining buyback capacity. At current prices around $8, that's another 12+ million shares they could retire. Management is clearly telegraphing that they believe the stock is undervalued — they're not wrong, given the $54.6 million net cash position and a forward P/E around 17x trailing earnings.

The DEA Play and the Texas Option

Two post-quarter events are worth noting for what they signal about Green Thumb's strategic direction.

First, the company submitted DEA registration applications for its state-licensed medical cannabis operations. Along with Curaleaf (which I covered yesterday), this makes Green Thumb one of the first MSOs to formally pursue federal compliance infrastructure. DEA registration is what allows facilities to handle Schedule III controlled substances within the CSA framework — and it's the foundational step toward any future scenario where cannabis companies access traditional banking, list on major exchanges, or participate in interstate commerce.

Second, Green Thumb was conditionally awarded a Texas Compassionate Use Program license for vertically integrated operations. Texas remains one of the most restrictive medical cannabis markets in the country, but it's also a 30-million-person state with only a handful of licensees. If Texas ever expands its program — and the political trajectory, while slow, points in that direction — early entrants will hold enormous competitive advantages. Green Thumb joining that market extends their footprint to 15 states.

What the Numbers Don't Tell You

The data says Green Thumb is executing well. Revenue growing, cash piling up, buyback in full swing, net cash positive, filing for DEA registration. By cannabis standards, this is the operator you'd want to own.

But the numbers obscure a structural tension that will define the next several quarters. The RYTHM brand licensing arrangement means Green Thumb's GAAP margins will compress starting Q2 even if the underlying business doesn't change. The $70 million annual fee is a structural drag on the operating company's reported profitability that only makes sense if you believe in the eventual RYTHM equity value as a Nasdaq-listed asset. If you're evaluating Green Thumb on reported GAAP earnings alone, the picture is about to get materially worse through no operational fault.

The comparison to Curaleaf is instructive. Curaleaf's $98.7 million tax benefit flattered Q1 earnings from a regulatory windfall; Green Thumb's $17 million arbitration settlement and $6.5 million RYTHM income did something similar on a smaller scale. Both companies are posting headline beats driven by items that won't recur (Ascend settlement) or are structurally new (RYTHM equity income). Both are dealing with gross margin compression from price wars. Both are filing for DEA registration.

The difference is capital structure. Green Thumb has $54.6 million in net cash. Curaleaf has net debt exceeding $400 million. Green Thumb is buying back shares. Curaleaf is servicing 11.5% senior secured notes. In an industry where access to capital remains structurally impaired, that gap matters more than any single quarter's earnings.

For The Green Cultivar portfolio, this is the operator that gives you the best downside protection with meaningful optionality if the regulatory environment continues to evolve. The 280E partial relief, the DEA filings, the RYTHM equity stake, and the Texas entry are all call options that cost nothing incremental — they're funded by an operating business that generates $76 million in cash flow per quarter and is still growing top line at 7%.

The question, as it was with Curaleaf, isn't whether Q1 was good. It's whether the architecture being built — the brand licensing structure, the dual-entity framework, the DEA registrations, the capital return program — amounts to preparation for a fundamentally different kind of cannabis company. Green Thumb is betting that it does. At $8.20 a share with net cash on the balance sheet, the market isn't pricing in much confidence that they're right.